MENU
+Compare
LABU
ETF ticker: NYSE ARCA
AS OF
Jul 3 closing price
Price
$61.54
Change
+$0.84 (+1.38%)
Net Assets
677.64M

LABU stock forecast, quote, news & analysis

The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the S&P Biotechnology Select Industry Index ("index")... Show more

Category: #Trading
LABU
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for LABU with price predictions
Jul 03, 2025

LABU's RSI Oscillator peaks and leaves overbought zone

The 10-day RSI Oscillator for LABU moved out of overbought territory on June 11, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 18 instances where the indicator moved out of the overbought zone. In of the 18 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LABU declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

LABU broke above its upper Bollinger Band on July 03, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 02, 2025. You may want to consider a long position or call options on LABU as a result. In of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for LABU just turned positive on July 03, 2025. Looking at past instances where LABU's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

LABU moved above its 50-day moving average on June 02, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for LABU crossed bullishly above the 50-day moving average on June 05, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LABU advanced for three days, in of 295 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 175 cases where LABU Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ABBVIE (NYSE:ABBV), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Exact Sciences Corp (NASDAQ:EXAS), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Arrowhead Pharmaceuticals (NASDAQ:ARWR).

Industry description

The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the S&P Biotechnology Select Industry Index ("index"). The fund, under normal circumstances, invests at least 80% of its net assets in financial instruments, such as swap agreements, securities of the index, and ETFs that track the index, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards ("GICS"). The fund is non-diversified.

Market Cap

The average market capitalization across the Direxion Daily S&P Biotech Bull 3X ETF ETF is 8.03B. The market cap for tickers in the group ranges from 120.07M to 322.43B. ABBV holds the highest valuation in this group at 322.43B. The lowest valued company is EBS at 120.07M.

High and low price notable news

The average weekly price growth across all stocks in the Direxion Daily S&P Biotech Bull 3X ETF ETF was 5%. For the same ETF, the average monthly price growth was 9%, and the average quarterly price growth was -36%. SCLX experienced the highest price growth at 20%, while ALT experienced the biggest fall at -38%.

Volume

The average weekly volume growth across all stocks in the Direxion Daily S&P Biotech Bull 3X ETF ETF was -37%. For the same stocks of the ETF, the average monthly volume growth was -57% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 79
Price Growth Rating: 56
SMR Rating: 87
Profit Risk Rating: 85
Seasonality Score: -4 (-100 ... +100)
View a ticker or compare two or three
LABU
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Trading

Profile
Fundamentals
Details
Category
Trading--Leveraged Equity
Address
Direxion Shares ETF Trust33 Whitehall Street,10th FloorNew York
Phone
866-476-7523
Web
http://www.direxioninvestments.com/